This research develops an affordable, scalable platform for recording electrical activity from brain organoids. Using innovative basket-shaped sensors made from a low-cost conductive material, the system enables simultaneous recording from dozens of mini-brains, accelerating drug discovery and improving our understanding of brain diseases with more human-relevant laboratory models.

This research critiques the Hatch-Waxman Act, arguing it enables pharmaceutical companies to extend monopolies through “evergreening,” delaying cheaper generics. It proposes legal reforms to restore balance between innovation and access, strengthen FDA oversight, and reduce drug costs, ensuring life-saving medications remain affordable for patients across the United States.